WO2004047820A1 - 温感パップ剤 - Google Patents
温感パップ剤 Download PDFInfo
- Publication number
- WO2004047820A1 WO2004047820A1 PCT/JP2003/015176 JP0315176W WO2004047820A1 WO 2004047820 A1 WO2004047820 A1 WO 2004047820A1 JP 0315176 W JP0315176 W JP 0315176W WO 2004047820 A1 WO2004047820 A1 WO 2004047820A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- warming
- adhesive layer
- support
- sensitive adhesive
- cataplasm
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a warming cataplasm comprising a support and an adhesive layer.
- a warming-imparting substance represented by capsaicin As a drug for imparting a warm feeling in the pressure-sensitive adhesive layer of a patch, a warming-imparting substance represented by capsaicin has been used. No. 1,435,073, Japanese Unexamined Patent Application Publication No. 6-256183, and Japanese Unexamined Patent Application Publication No. H10-290658. In order to sufficiently maintain the warm sensation when the patch is used, a relatively large amount of such a heat sensation-imparting substance had to be incorporated into the adhesive layer of the patch. However, when a large amount of the warming substance is incorporated into the pressure-sensitive adhesive layer in this manner, there is a problem of so-called residual irritancy, in which skin irritation remains even after the patch is peeled off.
- capsaicin has a strong residual irritancy, and when a bath containing a capsaicin-containing water-containing patch is applied to the skin and then bathed, the residual irritability (a tingling sensation such as piercing the skin) ) was very intolerable. For this reason, there has been a demand for a forcepsin-containing water-containing patch having sufficient warming effect of cabsaicin and reduced residual irritation in the patch.
- Japanese Patent Application Laid-Open No. 11-199552 discloses an external preparation for skin in which capsaicin is mixed with a predetermined amount of L-menthol as a cooling agent.
- L-menthol-containing topical skin preparations the problem of residual irritation due to force psicin remains, and the warming effect of capsaicin is relatively improved in combination with the cooling effect of L-menthol.
- the residual irritability tended to increase. Thus, no warming cataplasm having sufficiently reduced residual irritation has yet been obtained.
- the present invention has been made in view of the above-mentioned problems of the related art, and provides a sufficient warming effect, and also maintains a comfortable stimulus sustained by an appropriate warming effect.
- An object of the present invention is to provide a warming cataplasm that is further enhanced and has sufficiently reduced residual irritation.
- the present inventors have conducted intensive studies to achieve the above object, and found that L-menthol was added to the pressure-sensitive adhesive layer of the heat-sensitive cataplasm by mixing L-menthol and polyethylene glycol. Surprisingly, the warming effect of the warming-imparting substance such as cabsaicin has been improved relative to the cooling effect of polyethylene glycol, and the sustainability of comfortable stimulation accompanying the moderate warming effect has been further enhanced by polyethylene glycol. In addition, despite the above-mentioned effects being obtained during the use of the patch, polyethylenedaricol functions as a residual irritant after peeling, and the residual irritancy by a warming-imparting substance such as cabsaicin is sufficient.
- the warming cataplasm of the present invention (a warm water-containing patch) comprises: a support; and an adhesive layer disposed on at least one surface of the support.
- the adhesive layer contains a warming sensation substance, polyethylene glycol as an L-menthol and a residual irritation reducing agent.
- Examples of the warming-imparting substance include capsaicin, dihydroxycapsaicin, capsanthin, capsaicinoid, psipsicoside, tugarashi extract, tomato garnish tincture, I, pegaric powder, benzyl nicotinate, nicotinic acid j3—butoxyshetyl.
- a warming substance selected from the group consisting of N-acyl-l-ylamide (N-acyl-nilamide), p-nilyl amide noelate (n-l-l-amide), and vanillyl alcohol alkyl ether can be applied.
- the warming cataplasm of the present invention has a temperature Sensitive imparting substances from 0.001 to 0.1 mass 0 / o, L-menthol from 0.01 to 5 mass 0/0, and it is preferable that the polyethylene da recall each containing 3-25 wt%,
- the molecular weight of polyethylene glycol is preferably 200 to 4000, and the pressure-sensitive adhesive layer may further contain a non-steroid anti-inflammatory agent.
- the support used in the warming cataplasm of the present invention is a three-layer comprising a thermoplastic resin film and a fiber sheet made of a woven or nonwoven fabric disposed on both sides of the resin film.
- the support is structured.
- the support preferably has a moisture permeability (water vapor permeability) of 500 to 6000 g / m 2 Z for 24 hours.
- a moisture permeability water vapor permeability
- the moisture permeability can be measured according to the method specified in JISZ0208.
- FIG. 1 is a schematic sectional view showing one embodiment of the warming cataplasm of the present invention.
- FIG. 2 is a schematic cross-sectional view showing another embodiment of the warming cataplasm of the present invention.
- FIG. 1 is a schematic sectional view showing an embodiment of the warming cataplasm of the present invention.
- the warming cataplasm 10 shown in FIG. 1 includes a support 2 and an adhesive layer 1 disposed on at least one surface of the support 2, and the adhesive layer 1 is formed of a warming substance, L-men. Contains polyethylene glycol as a toile and residual irritation reducing agent.
- capsaicin N- (4-hydroxy-3-methoxybenzyl) -18-methyl-16-nonenamide
- dihydroxycapsa Capsaicin analogs such as isin, capsanthin, capsaicinoid, capsicoside, etc .
- Capsicum-derived warming substances derived from capsicum such as pepper extract, tugarashi tincture, tugarashi powder; benzil nicotinate; 13-butoxyshethyl nicotinic acid; Lilamide (N-acyldenylamide), noellic acid ⁇ -lylamide (nonylate phenylamide); vanillyl alcohol alkyl ether (the alkyl ether moiety preferably has 1 to 6 alkyl carbon atoms).
- the pepper-derived warming sensation-imparting substance usually contains capsaicin.
- the warming sensation-imparting substance may form a salt (sodium salt, potassium salt
- a warming substance derived from capsaicin or capsicum is preferred.
- the skin is stimulated, and a warming effect is obtained and a blood flow promoting effect is improved.
- the gentle stimulus lasts for a long time.
- the amount of the warming substance is not particularly limited, but the warming substance is preferably 0.001 to 0.1% by mass based on the total amount of the pressure-sensitive adhesive layer 1. , Preferably from 0.05 to 0.03% by mass, and more preferably from 0.01 to 0.03% by mass. If the compounding amount of the drug is less than the lower limit described above, sufficient stimulation of the skin by the warming substance will not be obtained, and the warming effect and blood flow promoting effect tend to be insufficient. If it exceeds the upper limit, irritation to the skin at the time of use of the patch tends to be excessive and the skin irritation and residual irritation after the patch is peeled off tend to be remarkable.
- L-menthol which is used as a drug, is a type of monoterpene alcohol and is the main component in peppermint oil. Such L-menthol has an effect of making the skin smooth with a refreshing feeling of use, and when used in combination with a warming substance, the warming effect of the warming substance can be further improved.
- the amount of L-menthol is not particularly limited, but is preferably from 0.01 to 5.0% by mass, and more preferably from 0.1 to 3.0% by mass, based on the total amount of the pressure-sensitive adhesive layer 1. It is more preferably 0 mass ° / 0 , and 0.5 to 1.5 mass. More preferably, it is / 0 .
- the amount of L-menthol is less than the above lower limit, the synergistic effect of improving the warm feeling by using it in combination with the warming substance tends to be insufficient.
- it exceeds the above upper limit crystals may be precipitated during long-term storage, and the cost may be high.
- the adhesive layer of the warming cataplasm contains polyethylene glycol. As described above, it is one of the features of the present invention to use polyethylene dalicol as a residual stimulus reducing agent.
- Polyethylene glycol is a polymer of ethylene glycol and is classified as polyether. Polyethylene glycol is generally produced by the polymerization of ethylene oxide, and both ends are generally hydroxyl groups.
- Polyethylene glycol having an average molecular weight of 200 to 400 is preferable.
- the average molecular weight is more preferably from 200 to 1500, further preferably from 200 to 600, and particularly preferably from 200 to less than 500.
- the average molecular weight is less than 200, it tends to be difficult to sufficiently obtain a pleasant stimulus sustaining effect and a residual stimulating effect.
- the above upper limits are exceeded, the workability becomes poor, and it becomes difficult to sufficiently obtain a comfortable stimulus persistence and a sufficient effect of reducing residual irritation.
- Polyethylene glycol is available from Dai-ichi Kogyo Seiyaku, Asahi Denka Kogyo, Sanyo Kasei Kogyo, Nippon Oil & Fats, and others.
- the blending amount of polyethylene glycol is based on the total amount of the pressure-sensitive adhesive layer 1.
- the content is preferably 3 to 25% by mass, more preferably 5 to 15% by mass. If the amount is less than the above lower limit, the effect of reducing residual irritation after peeling off the patch, especially the effect of reducing burning sensation when the body temperature rises due to bathing, etc., tends to be insufficient. If it exceeds, the adhesiveness of the adhesive layer tends to be insufficient.
- the pressure-sensitive adhesive layer 1 of the warming cataplasm 10 is composed of a water-soluble high-molecular compound forming the skeleton of the cataplasm, in addition to the warming-imparting substance, L-menthol and polyethylene glycol as a residual stimulus reducing agent. Contains water and hydrophilic high molecules such as molecules, water-absorbing polymers, and polymers that gel with water. In addition to these, various components that can be generally blended in the adhesive layer of the cataplasm, such as polyhydric alcohols, polyvalent metal salts, and surfactants, may be contained. [0260] The hydrophilic polymer functions as a base for the pressure-sensitive adhesive layer.
- gelatin for example, gelatin, polyacrylic acid or a salt thereof (a metal salt such as lithium, sodium, or potassium) or a partially neutralized product , Polybutyl alcohol, polyacrylamide, polyethylene oxide, polyethyleneimine, polybierpyrrolidone, carboxyvinyl polymer, methinoresenolerose, carboxymethylcellulose, hydroxyxetinorescellulose, each alone or in combination of two or more.
- a patch having good adhesiveness and shape retention can be obtained by using gelatin, polyacrylic acid or a salt thereof, a partially neutralized product and polyvinyl alcohol alone or in combination of two or more. It is possible to obtain.
- the compounding amount of the hydrophilic polymer is preferably from 5 to 25% by mass, more preferably from 8 to 20% by mass, based on the total amount of the pressure-sensitive adhesive layer 1. More preferably, the content is 10 to 15% by mass.
- the amount is less than the lower limit, the adhesive strength tends to be insufficient and the adhesive tends to peel off.
- the amount is more than the upper limit, the adhesive force becomes too strong, causing pain when peeling. Tend to cause problems.
- the amount to be blended is appropriately determined in consideration of the adhesiveness, cohesiveness, shape retention, water absorption capacity, nonuniformity of the plaster, reduced workability, reduced usability, viscosity during production, etc. of the preparation. Preferably.
- water contained in the pressure-sensitive adhesive layer purified water, sterilized water, natural water, or the like can be used.
- Water acts as a dispersing agent for the hydrophilic polymer and other components.
- it is important for dispersing and dissolving the glycols and polyhydric alcohols that function as humectants, which will be described later, uniformly in the formulation.
- water itself significantly improves the feeling of use at the time of use and after use, and has the effect of transferring to the skin together with moisturizing ingredients to give moisture and firmness.
- the compounding amount of water is preferably from 30 to 95% by mass, more preferably from 40 to 80% by mass, based on the total amount of the pressure-sensitive adhesive layer 1. 0-70 mass. / 0 is more preferable. If the amount is less than the above lower limit, the workability tends to decrease and the cost tends to increase. On the other hand, if the amount exceeds the above upper limit, it tends to be difficult to maintain the shape retention.
- the compounding amount is determined in consideration of the adhesiveness of the preparation, a decrease in water retention before use, a decrease in workability, a decrease in feeling during use, a shape retention before use, and the like.
- polyhydric alcohol examples include glycerin, ethylene glycol cornole, 1,3-butylene glycol, propylene glycol corn, dipropylene glycol, sorbitol, and xylitol.
- glycerin is particularly preferred because of good workability and feeling of use.
- the blending amount of the polyhydric alcohol is preferably 5 to 45% by mass, more preferably 15 to 35% by mass, based on the total amount of the pressure-sensitive adhesive layer 1. And more preferably 20 to 30% by mass. If the amount is less than the above lower limit, water in the preparation tends to volatilize at the time of application, and the adhesive strength tends to decrease and peel off.On the other hand, if the amount exceeds the upper limit, the adhesive strength further increases. Since no reinforcement can be obtained, it tends to be uneconomical.
- the polyvalent metal salts include, for example, aluminum hydroxide, aluminum hydroxide gel, hydrated aluminum silicate, synthetic aluminum silicate, and iron oxide.
- synthetic aluminum silicate and magnesium aluminate metasilicate are particularly preferred.
- the compounding amount of the polyvalent metal salt is preferably from 0.01 to 5% by mass, and more preferably from 0.05 to 3% by mass, based on the total amount of the pressure-sensitive adhesive layer 1. Is more preferably 0.1 to 2% by mass. If the amount is less than the above lower limit, the reaction does not proceed sufficiently and the gel strength tends to be insufficient.On the other hand, if the amount exceeds the above upper limit, the reaction rate during production is too fast to cause gelation. It tends to be uneven and workability is insufficient.
- organic acids such as EDTA, acetic acid, lactic acid, oxalic acid, citric acid, tartaric acid, etc., which have a chelating effect on metal ions, EDTA disodium, and citric acid
- Organic salts such as calcium, sodium citrate, and disodium citrate, and organic bases may be added.
- surfactant for example, sodium octylsulfosuccinate, alkyl sulfate, sodium 2-ethylhexylalkyl sulfate, sodium salt of normal dodecylbenzenesulfonate, etc.
- Ionic surfactants such as hexadecinoletrimethylammonium chloride, octadecyldimethinobenzobenolenoammonium chloride, polyoxyethylene dodecinolemonomethinoleammonium chloride, etc.
- polyoxyethylene stearyl ether polyoxyethylene hydrogenated castor oil, polyoxyethylene tridecyl ether, polyoxyethylene noninolefe / leatenorre, polyoxyethylene octylphenyl ether, polyoxyethylene monostearate, sodium Bitanmo Bruno stearate, sorbitan palmitate, sorbitan sesquioleate O-oleate, polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan Monooreeto, glycerol monostearate, polyglycerin fatty acid ester And non-ionic surfactants such as polyoxyethylene octadecylamine.
- polyoxyethylene monostearate and polyoxyethylene hydrogenated castor oil particularly preferred are polyoxyethylene monostearate and polyoxyethylene hydrogenated castor oil.
- the amount of the surfactant, based on the total amount of the adhesive layer 1, 0. 0 5 to 2 is preferably mass%, 0.2 to 1. 5 mass 0/0 More preferably, it is 0.4 to 1.0% by mass. If the amount is less than the lower limit, bleeding tends to occur. On the other hand, if the amount exceeds the upper limit, it is difficult to maintain shape retention.
- a skin-beautifying component if necessary, a skin-beautifying component, a non-steroid anti-inflammatory agent, a moisturizing component, an antioxidant, a cross-linking agent, a preservative, a tackifier, a solubilizing agent, a coloring agent , A fragrance, an ultraviolet absorber, an inorganic filler, a pH adjuster and the like can also be blended.
- indomethacin ketope oral phen, fuerbinac, flurbiprofen, ketorolac, piroxicam, oral xoprofen, ibuprofin piconol, diclofenac sodium and the like are preferred. used.
- the moisturizing component it is possible to use an aqueous solution of acylated kefiran, a malt extract, and daricols alone or in combination. But not the amount of these particularly limited, based on the total amount of the adhesive layer 1, preferably from 1 to 5 0 wt%, more preferably from 5 to 3 0 wt ° / 0, more preferably 5 ⁇ 25% by mass.
- the compounding amount is determined in consideration of the adhesiveness and cohesiveness of the drug product, the decrease in water retention and shape retention before use, the unevenness of the gel, the decrease in workability, the decrease in usability during use, etc. Is preferred.
- polypropylene glycol having an average molecular weight of 500 to 300 which is a glycol having a polyether structure, is preferable.
- antioxidant ascorbic acid, propyl gallate, butylhydroxyanisole, dibutinolehydroxytoluene, nonoresinia diggaretic acid, tocopherol, tocopherol acetate, natural vitamin E, etc. can be used. It is.
- the crosslinking agents include thermosetting resins such as poorly water-soluble aluminum compounds, polyfunctional epoxy compounds, amino resins, funols, epoxy resins, alkyd resins, unsaturated polyesters, and isocyanates.
- thermosetting resins such as poorly water-soluble aluminum compounds, polyfunctional epoxy compounds, amino resins, funols, epoxy resins, alkyd resins, unsaturated polyesters, and isocyanates.
- a compound, a block isocyanate compound, an organic crosslinking agent, and an inorganic crosslinking agent such as a metal or a metal compound can be used alone or in combination.
- tackifier examples include casein, pullulan, agar, dextran, sodium alginate, soluble starch, carboxystarch, dextrin, carboxymethisoresenorelose, carboxymethose / resenorelose sodium, methinole Senorelose, etinoresenorelose, hydroxyxetinoresenorelose, polyvinylinoleanol, polyethylene oxide, polyacrylamide, polyacrylic acid, polyvinylinolepyrrolidone, canolepoxyvinylinolepolymer, polyvinylinoleatenole , Maleic acid copolymer, methoxyethylene maleic anhydride copolymer, isobutylene maleic anhydride copolymer,
- solubilizers examples include isopropyl iso-myristate, di-isopropyl adipate, crotamiton, and olive oil. Of these, isopropyl myristate is particularly preferred.
- the amount of these components is preferably 0.2 to 3% by mass, more preferably 0.5 to 2% by mass, and particularly preferably 0.8 to 0.5% by mass, based on the total amount of the pressure-sensitive adhesive layer 1. It is.
- Red No. 2 (Amaranth), Red No. 3 (Erythrosin), Red No. 102 (Neucoccin), Red No. 104 (1) (Proxin B), Red No. 105 (1) (Rose Bengal), Red No. 106 (Acid Dressed), Yellow No. 4 (Tartrazine), Yellow No. 5 (Sunset Yellow FCF), Green No. 3 '(Fast Green FCF) ), Blue No. 1 (Priant Blue FCF), Blue No. 2 (indigo carmine) and other legal dyes.
- the pigment is not particularly limited, but it has a significant effect on the formulation image and leads to an improvement in the feeling of use / activation of the skin.
- fragrance examples include heart oil, keich oil, cinnamon oil, fennel oil, castor oil, turpentine oil, eucalyptus oil, orange oil, lavender oil, lemon oil, rose oil, lemongrass oil and the like. Distribution of plant extracts such as rosemary and sage It is possible to combine.
- Examples of the ultraviolet absorber include paraaminobenzoic acid, paraaminobenzoic acid ester, amyl paradimethylaminobenzoic acid, salicylate, methyl anthranilate, umbelliferone, esculin, benzyl cinnamate, shino Xates, guaiazulene, perocanic acid, 21- (2-hydroxy-15-methinole feninole) benzotriazonole, 4-methoxybenzophenone, 2-hydroxy-14-methoxybenzophenone, dioxybenzone, octabenzone, dihigin It is possible to add droxydimethoxybenzophenone, slisobenzone, benzoresonoresinole, octyldimethylparaaminobenzoate, ethylhexylparamethoxycinnamate and the like.
- Examples of the inorganic filler include calcium carbonate, magnesium carbonate, silicates (eg, aluminum silicate, magnesium silicate, and the like), silicate, potassium sulfate, calcium sulfate, calcium zincate, and oxides. Zinc and titanium oxide can be used.
- the above pH adjusters include acetic acid, formic acid, lactic acid, tartaric acid, oxalic acid, benzoic acid, glycolic acid, malic acid, citric acid, hydrochloric acid, nitric acid, sulfuric acid, sodium hydroxide, and hydroxide.
- the pH value of the mixed solution (plaster) prepared by appropriately mixing the above-mentioned respective components so as not to irritate the skin and that: H of the mixed solution is as follows: It is preferably from 8 to 8, more preferably from 5 to 7.
- H of the mixed solution is as follows: It is preferably from 8 to 8, more preferably from 5 to 7.
- the amount of these additives is not particularly limited, but the total amount of these additives is preferably 5 to 70% by mass, more preferably 20 to 60% by mass, based on the total amount of the pressure-sensitive adhesive layer 1. Is more preferable.
- the pressure-sensitive adhesive layer 1 described above is disposed on the support 2, and has a warm feeling.
- the support 2 used for the backing agent 10 may be any as long as it can support the pressure-sensitive adhesive layer 1 and may be a stretchable or non-stretchable support.
- a sheet or a resin film can be used.
- a fiber sheet made of a woven or nonwoven fabric having water vapor permeability is preferable. When such a fiber sheet support is used, sweat accumulated between the affected area and the patch at the time of application can be effectively diffused, and it is possible to prevent irritating skin irritation due to sweat. .
- the support 2 specifically, polyurethane, polyester, polypropylene, polyvinyl acetate, polyvinylidene chloride, polyethylene, polyethylene terephthalate, aluminum sheet, nylon, acrylic, cotton, rayon, Synthetic fibers or natural fibers such as acetate, or a fiber sheet made of a woven or nonwoven fabric by combining these fibers, and a fiber sheet made of a composite material of these and a film having water vapor permeability, and the like.
- a woven or nonwoven fiber sheet made of polyester, polyethylene, or polyethylene terephthalate is preferable from the viewpoint of safety, versatility, and stretchability, and a woven or nonwoven fabric made of polyethylene terephthalate is preferred.
- Fiber sheet is more preferable.
- Such a fiber sheet has flexibility, is easy to follow the skin, and has low skin irritation even though it is thick. Furthermore, it is possible to obtain a patch having a suitable self-supporting property by using a fiber sheet.
- the thickness of the support 2 is preferably from 400 to 200 ⁇ , more preferably. Or 600-1000 m.
- the anchoring property tends to be insufficient
- the thickness exceeds the above upper limit a feeling of incongruity tends to occur at the time of application.
- the moisture permeability of the support 2 is preferably 500 ⁇ 6000 g / m 2/24 hr , more preferably 2000 ⁇ 6000 g / m 2/24 hr, 3000 ⁇ 5000 g further preferably / m 2/24 hr. If the moisture permeability of the support is less than the lower limit, it tends to cause irritating rash. On the other hand, if it exceeds the upper limit, an appropriate moisture retention effect by the ODT effect tends to be hardly obtained.
- the moisture permeability water vapor permeability
- JISZ0208 JISZ0208.
- the warming cataplasm 20 shown in Fig. 2 is a support 2 having a three-layer structure including a thermoplastic resin film 2b and a fiber sheet 2a made of a woven or nonwoven fabric disposed on both sides thereof.
- the pressure-sensitive adhesive layer 1 is provided on one of the surfaces.
- the fiber sheet 2a preferably has a basis weight (weight per unit area) of 10 to 20 OgZm 2 , and more preferably a basis weight of 50 to 15 OgZm 2 . If the basis weight is less than the above lower limit, not only is the handling of the patch inadequate, but also the cushioning properties are poor and the improvement in foreign body sensation tends to be insufficient. On the other hand, when the content exceeds the upper limit, the cushioning property is increased but the whole is hardened, and the skin irritation tends to be increased.
- the thickness of the fiber sheet 2a is preferably from 10 to 200 m, and more preferably from 50 to 150 m.
- the thickness is less than the above lower limit, the anchoring property tends to be insufficient.
- the thickness exceeds the above upper limit, a feeling of incongruity at the time of sticking tends to occur.
- the thermoplastic resin film 2b for example, polyester, polyethylene, polypropylene, polyurethane, polyamide (nylon), polyacetal, polycarbonate, polyvinyl chloride, ABS resin, polystyrene, (meth) acrylic
- a resin film made of a resin is exemplified. Among these, a resin film made of polyester or polyethylene is particularly preferred.
- thermoplastic resin film 2b By using the thermoplastic resin film 2b to form the support 2 into a three-layer structure, there is almost no drug loss due to the transfer of the drug into the support 2, and the patch is applied to the skin. When pasted, it becomes possible to obtain a patch 20 having an appropriate ODT (sealing and wrapping method) effect by sealing and an appropriate heat retaining effect.
- the thickness of the thermoplastic resin film 2b is preferably from 10 to: L00 ⁇ m, more preferably from 15 to 30 / ⁇ .
- the thickness is less than the above lower limit, self-supporting properties cannot be maintained when a patch is produced, so that it tends to be difficult to stick, and the barrier effect of the drug is low and the sealing effect may be insufficient.
- the value exceeds the upper limit, the ability to follow the application site is insufficient, and the user tends to feel uncomfortable, and the application site tends to be damaged.
- the patch 20 provided with the support 2 having a three-layer structure has an appropriate self-supporting property, and can support and fix an affected part such as a backache and a muscular pain.
- an affected part such as a backache and a muscular pain.
- the site sealed with the patch 20 may be a layer of the stratum corneum softening and swelling due to the stored skin moisture, and the barrier property of the skin may be reduced, so that the warming substance or the drug may be removed. Transdermal absorption is significantly increased.
- the thickness of the support 2 having a three-layer structure is preferably from 100 to 1200 ⁇ m, and more preferably from 300 to 900 ⁇ m. When the thickness is less than the above lower limit, the anchoring property tends to be insufficient. Tend to be sick.
- the moisture permeability of the support body 2 of the three-layer structure is preferably 500 ⁇ 6000 g / m 2/24 hr , more preferably 2000 ⁇ 6000 g / m 2/24 hr, 3000 further preferably 5000 g / m 2/24 hr . If the moisture permeability of the support is lower than the lower limit, rash and plaster sag tends to occur. On the other hand, if the upper limit is exceeded, an appropriate moisturizing effect due to the ODT effect tends not to be obtained.
- thermoplastic resin is poured between two fiber sheets 2a, and the mixture is passed through a roll before the thermoplastic resin is solidified and laminated.
- the support 2 having a three-layer structure including the resin film 2b and the fiber sheet 2a is obtained.
- the color of the support is not particularly limited, but it is colored white, flesh-colored, yellow, red, orange, green, pink, light blue, or the like, because it leads to an improvement in the feeling of use and the activation of the skin. Preferably.
- the warming cataplasms 10 and 20 are formed by arranging the above-described pressure-sensitive adhesive layer 1 on at least one surface of the support 2.
- the method of arranging the pressure-sensitive adhesive layer 1 on the support 2 is not particularly limited. .
- a uniform mixture is obtained by mixing a drug, various components that can be generally blended in the pressure-sensitive adhesive layer, and a mixture of the above-mentioned other components that are added as necessary, with a stirrer. By applying or spreading this on the support 2, warming cataplasms 10, 20 can be obtained.
- the warming cataplasm may have one pressure-sensitive adhesive layer as shown in Figs. 1 and 2, or two layers as long as the skin permeability of the drug is not impaired. It may have the above-mentioned pressure-sensitive adhesive layer (not shown).
- the thickness of the pressure-sensitive adhesive layer 1 is not particularly limited, but is preferably 20 to 200 ⁇ m. If the thickness of the pressure-sensitive adhesive layer 1 is less than the lower limit, the skin permeability of the drug tends to be insufficient.On the other hand, if the thickness exceeds the upper limit, the pressure-sensitive adhesive remains on the skin after application. Phenomenon (adhesive residue) tends to occur.
- the patches 10 and 20 further include a release paper (not shown) on the pressure-sensitive adhesive layer 1
- the mixture is applied to the release paper and then applied to the coating surface.
- the patches 10 and 20 further include release paper as described above
- examples of such release paper include polyester such as polyethylene terephthalate, polyvinyl chloride, and polyvinylidene chloride. And a laminated film of high-quality paper and polyolefin.
- the warming cataplasms 10 and 20 thus obtained are preferably used after being appropriately cut into a predetermined shape.
- a predetermined shape In other words, for the purpose of using it for a part of the body, it is necessary to process it into a shape that can be applied well to the target part such as chest, back, arm, foot, waist, shoulder etc. it can.
- the patch is desirably stored in a hermetically sealed bag or container until use from the viewpoint of preventing contamination during storage and a reduction in effects due to evaporation of volatile substances.
- Example 1 [0079] Purified water 55. 55%, Gelatin 3%, Polyacrylic acid 3%, Partially neutralized polyatacrylic acid 3%, Polybutyl alcohol 2%, Synthetic aluminum silicate 1%, Alumina metasilicate Magnesium 0.3%, polyoxyethylene monostearate 0.5%, disodium ethylenediaminetetraacetate 0.3%, methyl paraben 0.2%, glycerin 20%, polyethylene glycolone 10. The mixture was stirred until 1.0% of L-Mentol and 0.15% of 10% Pepper Extract were uniformly dispersed and dissolved to obtain a coating liquid for forming the pressure-sensitive adhesive layer 1. The amount of capsaicin in the coating solution was 0.015%. In addition, McGall 400 with a molecular weight of 400 was used for polyethylene glycol.
- the coating liquid was spread on the support 2 so as to be 1000 GZm 2, was stuck to the film. Then, it was cut into 10 cm x 14 cm to obtain a sheet-like warming cataplasm. .
- the composition of the support 2 used in Example 1, a polyester nonwoven fabric (basis weight 50 g / m 2) Bruno polyethylene film (thickness 1 5 ⁇ ) / polyester nonwoven fabric (basis weight 50 g / m 2 ) is a support of the three-layer structure, the moisture permeability was 3800 g / m 2/2 4 hr. The moisture permeability was measured at a temperature of 40 ° C and a relative humidity of 90% according to the method specified in JISZ0208.
- a warming cataplasm was obtained in the same manner as in Example 1 except that the amount of glycerin in the coating liquid in Example 1 was changed to 30% and polyethylene glycol was not mixed.
- a warming cataplasm was obtained in the same manner as in Example 1 except that 10% of a 70% aqueous solution of sorbitol was used in place of polyethylene glycol in the coating liquid in Example 1.
- Example 3 (Comparative Example 3) A warming cataplasm was obtained in the same manner as in Example 1 except that 10% of liquid paraffin was blended in place of polyethylene daly cone in the coating liquid in Example 1.
- a residual irritation test was performed as follows using the warming cataplasms obtained in Example 1 and Comparative Examples 1 to 3. First, the patch was applied to the waist of 30 adults (panels), and the condition was maintained for 8 hours. Next, the patch was peeled off, and after one hour had elapsed, all the pannels were bathed.
- Example 1 As is clear from the results shown in Table 1, the warming cataplasm obtained in Example 1 had sufficiently reduced residual irritation, and after the warming cataplasm was removed. It was confirmed that comfortable bathing was possible in. On the other hand, when the warming cataplasms of Comparative Examples 1 to 3 were used, there was a problem of residual irritation, and it was confirmed that some of the panelers could not stand the burning sensation during bathing. In addition, at the time of pasting The warming cataplasm obtained in Example 1 was also favorable in terms of warm feeling, refreshing feeling, and sustainability thereof.
- polyethylene dalicol was confirmed to be particularly suitable as a residual irritation reducing agent for sufficiently reducing residual irritation.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004555065A JP4467437B2 (ja) | 2002-11-27 | 2003-11-27 | 温感パップ剤 |
KR1020057009494A KR101166004B1 (ko) | 2002-11-27 | 2003-11-27 | 온감 파프제 |
US10/536,501 US20060093656A1 (en) | 2002-11-27 | 2003-11-27 | Warming patch |
EP03775929.7A EP1568365B1 (en) | 2002-11-27 | 2003-11-27 | Warm poultice |
AU2003284472A AU2003284472A1 (en) | 2002-11-27 | 2003-11-27 | Warm poultice |
BRPI0316616A BRPI0316616B8 (pt) | 2002-11-27 | 2003-11-27 | emplastro térmico com efeito térmico suficiente que torna a sensação agradável mais duradoura e irritação residual mais reduzida |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002344398 | 2002-11-27 | ||
JP2002-344398 | 2002-11-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004047820A1 true WO2004047820A1 (ja) | 2004-06-10 |
Family
ID=32375947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/015176 WO2004047820A1 (ja) | 2002-11-27 | 2003-11-27 | 温感パップ剤 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20060093656A1 (ja) |
EP (1) | EP1568365B1 (ja) |
JP (1) | JP4467437B2 (ja) |
KR (1) | KR101166004B1 (ja) |
CN (1) | CN100372526C (ja) |
AU (1) | AU2003284472A1 (ja) |
BR (1) | BRPI0316616B8 (ja) |
WO (1) | WO2004047820A1 (ja) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006083510A (ja) * | 2004-08-19 | 2006-03-30 | Chisso Corp | 耐l−メントール性を有する弾性繊維、弾性不織布及びこれらを用いた繊維製品 |
JP2006232770A (ja) * | 2005-02-28 | 2006-09-07 | Kanebo Ltd | 外用組成物及びそれを含有する外用剤 |
WO2008150120A1 (en) * | 2007-06-08 | 2008-12-11 | Samyang Corporation | Matrix-type transdermal drug delivery system and preparation method thereof |
JP2010083824A (ja) * | 2008-09-30 | 2010-04-15 | Kobayashi Pharmaceut Co Ltd | 外用鎮痛組成物 |
WO2011155542A1 (ja) * | 2010-06-09 | 2011-12-15 | 花王株式会社 | 水蒸気発生温熱具 |
JP2016140300A (ja) * | 2015-01-30 | 2016-08-08 | ハウスウェルネスフーズ株式会社 | トウガラシ抽出物及び/又はショウガ抽出物を含む組成物、ならびにその製造方法 |
JPWO2016136556A1 (ja) * | 2015-02-24 | 2017-09-28 | 久光製薬株式会社 | パップ剤 |
JP2018501194A (ja) * | 2014-10-31 | 2018-01-18 | アヴェント インコーポレイテッド | 膀胱収縮の抑制に関連する用途のための方法および装置 |
WO2019146613A1 (ja) | 2018-01-24 | 2019-08-01 | 久光製薬株式会社 | 貼付剤 |
WO2019146614A1 (ja) | 2018-01-24 | 2019-08-01 | 久光製薬株式会社 | 貼付剤 |
US11903915B2 (en) | 2019-02-14 | 2024-02-20 | Hisamitsu Pharmaceutical Co., Inc. | Poultice |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2535045T3 (es) | 2003-04-10 | 2015-05-04 | Vanderbilt Royalty Sub L.P. | Usos y composiciones para administración de capsaicina |
WO2006105481A1 (en) * | 2005-03-30 | 2006-10-05 | Neurogesx, Inc. | Low-concentration capsaicin patch and methods for treating neuropathic pain |
JP5698120B2 (ja) * | 2008-04-15 | 2015-04-08 | フイルメニツヒ ソシエテ アノニムFirmenich Sa | 温感組成物 |
WO2009142993A1 (en) * | 2008-05-21 | 2009-11-26 | The Regents Of The University Of California | Topical application of analgesic for pain relief |
EP2671593B1 (en) * | 2011-02-02 | 2017-06-07 | Nitto Denko Corporation | Patch preparation |
JP5688183B2 (ja) * | 2011-03-30 | 2015-03-25 | ▲海▼洋王照明科技股▲ふん▼有限公司 | 基板及びその製造方法、ならびに当該基板を使用する有機電界発光デバイス |
US20130224280A1 (en) * | 2012-02-23 | 2013-08-29 | Rita Toth | Transdermal compositions and methods for treating stretch marks |
FR2991586B1 (fr) * | 2012-06-08 | 2014-05-30 | Gergonne Sas | Bande elastique de contention chauffante |
CN102813956B (zh) * | 2012-08-17 | 2015-12-02 | 天津市中科健新材料技术有限公司 | 一次性卫生用品用的温热暖肤剂组合物及其制备方法 |
KR101351841B1 (ko) * | 2013-08-28 | 2014-01-15 | 윤경 | 쿨링 및 히팅 기능을 갖는 셀룰로오즈 패치 |
ITMI20131532A1 (it) * | 2013-09-17 | 2015-03-18 | Altergon Sa | Cerotto freddo-caldo |
JP5671180B1 (ja) * | 2014-07-30 | 2015-02-18 | ユニ・チャーム株式会社 | 使い捨ての化粧パッド |
US20170348248A1 (en) * | 2014-12-22 | 2017-12-07 | Hisamitsu Pharmaceutical Co., Inc. | Gel Patch |
CN105709189A (zh) * | 2016-02-16 | 2016-06-29 | 广东泰宝医疗科技股份有限公司 | 一种温感理疗镇痛剂的制备方法 |
CN106073982A (zh) * | 2016-06-16 | 2016-11-09 | 广州仁益医疗器械有限公司 | 阴囊医用降温贴 |
JP6635881B2 (ja) * | 2016-06-27 | 2020-01-29 | ユニ・チャーム株式会社 | 温感シート |
KR102414416B1 (ko) * | 2016-06-27 | 2022-06-28 | 유니 참 코포레이션 | 온감 시트 |
CN110114064A (zh) * | 2016-12-28 | 2019-08-09 | 久光制药株式会社 | 贴剂 |
CN108078676A (zh) * | 2017-12-12 | 2018-05-29 | 成都美益达医疗科技有限公司 | 一种治疗关节部位伤口的敷贴 |
JP7085836B2 (ja) * | 2017-12-28 | 2022-06-17 | ユニ・チャーム株式会社 | 吸収性物品、吸収性物品用の温感部材、及び温感部材の吸収性物品に貼付しての使用 |
CN110721027A (zh) * | 2019-09-04 | 2020-01-24 | 亳州市新健康科技有限公司 | 一种透气可视护创帖及其生产方法 |
JP2021122321A (ja) * | 2020-01-31 | 2021-08-30 | ユニ・チャーム株式会社 | 吸収性物品 |
US11872320B2 (en) | 2021-02-25 | 2024-01-16 | Hisamitsu Pharmaceutical Co., Inc. | Method for treating osteoarthritis |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03161435A (ja) | 1989-11-20 | 1991-07-11 | Lion Corp | 貼付剤 |
JPH06256183A (ja) | 1993-03-09 | 1994-09-13 | Sekisui Chem Co Ltd | 消炎鎮痛貼付剤 |
JPH10298065A (ja) | 1997-04-24 | 1998-11-10 | Taisho Pharmaceut Co Ltd | 温感貼付剤 |
JPH11199522A (ja) | 1997-12-26 | 1999-07-27 | Lion Corp | 触感増強方法及び皮膚外用剤 |
JP2000143507A (ja) | 1998-11-13 | 2000-05-23 | Maruishi Pharmaceutical Co Ltd | カプサイシン含有外用剤 |
WO2001010435A1 (fr) | 1999-08-05 | 2001-02-15 | Taisho Pharmaceutical Co., Ltd. | Timbre |
US6469227B1 (en) | 1999-12-10 | 2002-10-22 | Lectec Corporation | Antipruritic patch |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU464487B2 (en) * | 1971-06-16 | 1975-08-11 | Colgate-Palmolive Pty. Ltd. | Light duty detergent formulations |
JPH10298066A (ja) * | 1997-04-24 | 1998-11-10 | Taisho Pharmaceut Co Ltd | 温感貼付剤 |
JP2002029993A (ja) * | 1999-08-05 | 2002-01-29 | Taisho Pharmaceut Co Ltd | 貼付剤 |
-
2003
- 2003-11-27 KR KR1020057009494A patent/KR101166004B1/ko active IP Right Grant
- 2003-11-27 EP EP03775929.7A patent/EP1568365B1/en not_active Expired - Lifetime
- 2003-11-27 CN CNB2003801044153A patent/CN100372526C/zh not_active Expired - Fee Related
- 2003-11-27 JP JP2004555065A patent/JP4467437B2/ja not_active Expired - Lifetime
- 2003-11-27 AU AU2003284472A patent/AU2003284472A1/en not_active Abandoned
- 2003-11-27 BR BRPI0316616A patent/BRPI0316616B8/pt not_active IP Right Cessation
- 2003-11-27 US US10/536,501 patent/US20060093656A1/en not_active Abandoned
- 2003-11-27 WO PCT/JP2003/015176 patent/WO2004047820A1/ja active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03161435A (ja) | 1989-11-20 | 1991-07-11 | Lion Corp | 貼付剤 |
JPH06256183A (ja) | 1993-03-09 | 1994-09-13 | Sekisui Chem Co Ltd | 消炎鎮痛貼付剤 |
JPH10298065A (ja) | 1997-04-24 | 1998-11-10 | Taisho Pharmaceut Co Ltd | 温感貼付剤 |
JPH11199522A (ja) | 1997-12-26 | 1999-07-27 | Lion Corp | 触感増強方法及び皮膚外用剤 |
JP2000143507A (ja) | 1998-11-13 | 2000-05-23 | Maruishi Pharmaceutical Co Ltd | カプサイシン含有外用剤 |
WO2001010435A1 (fr) | 1999-08-05 | 2001-02-15 | Taisho Pharmaceutical Co., Ltd. | Timbre |
US6469227B1 (en) | 1999-12-10 | 2002-10-22 | Lectec Corporation | Antipruritic patch |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006083510A (ja) * | 2004-08-19 | 2006-03-30 | Chisso Corp | 耐l−メントール性を有する弾性繊維、弾性不織布及びこれらを用いた繊維製品 |
JP2006232770A (ja) * | 2005-02-28 | 2006-09-07 | Kanebo Ltd | 外用組成物及びそれを含有する外用剤 |
WO2008150120A1 (en) * | 2007-06-08 | 2008-12-11 | Samyang Corporation | Matrix-type transdermal drug delivery system and preparation method thereof |
US8404277B2 (en) | 2007-06-08 | 2013-03-26 | Samyang Biopharmaceuticals Corporation | Matrix-type transdermal drug delivery system and preparation method thereof |
JP2010083824A (ja) * | 2008-09-30 | 2010-04-15 | Kobayashi Pharmaceut Co Ltd | 外用鎮痛組成物 |
WO2011155542A1 (ja) * | 2010-06-09 | 2011-12-15 | 花王株式会社 | 水蒸気発生温熱具 |
US20130079851A1 (en) * | 2010-06-09 | 2013-03-28 | Kyouko Tagami | Steam-Generative Warming Device |
RU2582454C2 (ru) * | 2010-06-09 | 2016-04-27 | Као Корпорейшн | Парогенерирующее устройство обогрева |
US9931241B2 (en) | 2010-06-09 | 2018-04-03 | Kao Corporation | Steam-generative warming device |
JP2018501194A (ja) * | 2014-10-31 | 2018-01-18 | アヴェント インコーポレイテッド | 膀胱収縮の抑制に関連する用途のための方法および装置 |
JP2016140300A (ja) * | 2015-01-30 | 2016-08-08 | ハウスウェルネスフーズ株式会社 | トウガラシ抽出物及び/又はショウガ抽出物を含む組成物、ならびにその製造方法 |
JPWO2016136556A1 (ja) * | 2015-02-24 | 2017-09-28 | 久光製薬株式会社 | パップ剤 |
WO2019146613A1 (ja) | 2018-01-24 | 2019-08-01 | 久光製薬株式会社 | 貼付剤 |
WO2019146614A1 (ja) | 2018-01-24 | 2019-08-01 | 久光製薬株式会社 | 貼付剤 |
KR20200105894A (ko) | 2018-01-24 | 2020-09-09 | 히사미쓰 세이야꾸 가부시키가이샤 | 첩부제 |
KR20200106175A (ko) | 2018-01-24 | 2020-09-11 | 히사미쓰 세이야꾸 가부시키가이샤 | 첩부제 |
US11166921B2 (en) | 2018-01-24 | 2021-11-09 | Hisamitsu Pharmaceutical Co., Inc. | Patch |
US11400053B2 (en) | 2018-01-24 | 2022-08-02 | Hisamitsu Pharmaceutical Co., Inc. | Patch containing nonylic acid vanillylamide |
US11903915B2 (en) | 2019-02-14 | 2024-02-20 | Hisamitsu Pharmaceutical Co., Inc. | Poultice |
Also Published As
Publication number | Publication date |
---|---|
JPWO2004047820A1 (ja) | 2006-03-23 |
BRPI0316616B8 (pt) | 2021-07-27 |
US20060093656A1 (en) | 2006-05-04 |
EP1568365B1 (en) | 2018-04-11 |
JP4467437B2 (ja) | 2010-05-26 |
KR101166004B1 (ko) | 2012-07-18 |
BR0316616A (pt) | 2005-12-20 |
EP1568365A4 (en) | 2011-06-08 |
BRPI0316616B1 (pt) | 2018-05-15 |
AU2003284472A1 (en) | 2004-06-18 |
CN100372526C (zh) | 2008-03-05 |
CN1717226A (zh) | 2006-01-04 |
KR20050086858A (ko) | 2005-08-30 |
EP1568365A1 (en) | 2005-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4467437B2 (ja) | 温感パップ剤 | |
JP4398158B2 (ja) | 貼付剤 | |
JPH07506562A (ja) | 植物油ベースの皮膚透過促進剤組成物,およびそれに関連する方法ならびにシステム | |
KR100647480B1 (ko) | 박지 형태의 첩부제 | |
WO2001047559A9 (fr) | Pastilles a usage externe | |
WO2002032431A1 (fr) | Compositions pour preparations externes | |
JP2569396B2 (ja) | 経皮投与型薬物用貼付剤 | |
JP5089933B2 (ja) | 含水系粘着剤組成物及びそれを用いた貼付剤 | |
KR100946605B1 (ko) | 소염 진통 첩부제 | |
WO2013126697A1 (en) | Transdermal compositions and methods for treating stretch marks | |
JP3466305B2 (ja) | 溶解剤および該溶解剤を含有する外用製剤 | |
JP5350575B2 (ja) | シート状パック剤及びその製造方法 | |
JP4073398B2 (ja) | シート状パック剤 | |
JPH057369B2 (ja) | ||
CN101686950B (zh) | 巴布剂及巴布剂的制造方法 | |
KR20210065931A (ko) | 함수계 첩부제 | |
JP4744439B2 (ja) | 貼付剤 | |
JPS5936608A (ja) | 新規貼付薬 | |
JPS63145222A (ja) | 腰痛用貼付剤 | |
TW201139605A (en) | Hydrous adhesive patch | |
JP4536844B2 (ja) | シート状パック剤 | |
JP2887548B2 (ja) | 使用性の改善された含水性皮膚外用貼付剤 | |
JPH10298065A (ja) | 温感貼付剤 | |
JPH10298066A (ja) | 温感貼付剤 | |
JPS63284124A (ja) | 湿布剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004555065 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057009494 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038A44153 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003775929 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200500864 Country of ref document: VN |
|
ENP | Entry into the national phase |
Ref document number: 2006093656 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10536501 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057009494 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003775929 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0316616 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 10536501 Country of ref document: US |